Nephrolithiasis and Polycystic Ovary Syndrome: A Case-Control Study Evaluating Testosterone and Urinary Stone Metabolic Panels
Table 2
Bivariate analysis using categorical testosterone levels within the PCOS cohort.
High testosterone (n = 38)
Normal testosterone (n = 36)
value
N
Mean ± SD age (range)
32.4 ± 8.2
(14.9–57.0)
39.7 ± 13.8
(13.63–73.69)
0.008
74
Mean ± SD kg/m2 BMI (range)
34.3 ± 7.0
(21.0–54.5)
27.9 ± 6.3
(17.93–48.79)
<0.001
74
Mean ± SD 24 hr urine panel (range)
Calcium (mg/day)
223.7 ± 158.5
(35.5–913.6)
198.3 ± 87.7
(50.5–366.7)
0.426
65
Citrate (mg/day)
709.6 ± 411.7
(118–1903)
517.1 ± 257.9
(82–956
0.041
54
Creatinine (g/day)
1.3 ± 0.5
(0.6–3.2)
1.2 ± 0.3
(0.6–1.6)
0.224
56
Oxalate (mg/day)
37.6 ± 12.3
(17–66)
39.3 ± 18.3
(19–113)
0.681
58
Sodium (mmol/day)
144.4 ± 54.1
(49–282)
123.8 ± 47.8
(52–283)
0.154
52
Uric acid (mg/day)
565.3 ± 225.2
(179–1016)
461.4 ± 126.9
(208–739)
0.028
60
Volume (ml/day)
1721.8 ± 822.9
(581–3440)
1561.1 ± 769.6
(590–3259)
0.466
53
No. abnormality (%)
Hypercalciuria (>200 mg/day)
17
(51.5%)
18
(56.3%)
0.893
65
Hypocitraturia (<550 mg/day)
11
(36.7%)
13
(54.2%)
0.312
54
Hyperoxaluria (>40 mg/day)
13
(41.9%)
7
(25.9%)
0.316
58
Hypernatriuria (>150 mmol/day)
12
(40.0%)
3
(13.6%)
0.078
52
Hyperuricosuria (>750 mg/day)
8
(23.5%)
0
(0%)
0.008
60
Low volume (<2000 ml/day)
17
(63.0%)
18
(69.2%)
0.848
53
Mean ± SD stone composition % (range)
CaOMH
35.7 ± 31.8
(0–80)
59.0 ± 26.0
(0–90)
0.062
24
CaODH
16.4 ± 17.8
(0–60)
17.5 ± 21.5
(0–50)
0.899
24
CaPh
31.4 ± 31.8
(0–90)
16.5 ± 23.3
(0–80)
0.199
24
CaHPh
7.9 ± 22.3
(0–80)
—
—
0.209
24
MAP
4.3 ± 16.0
(0–60)
—
—
0.336
24
UA
0.7 ± 2.7
(0–10)
3.0 ± 6.8
(0–20)
0.332
24
No. greater than 70% mixed (%)
7
(50%)
4
(40%)
1.000
24
No adjustments made for confounding variables, original analysis only, and therefore, values not referenced in discussion. Stones qualified as pure if the dominant component made up ≥70% of the stone.
